

In vitro testing of *in silico* designed Cationic Antimicrobial Peptides

Natalie Kuljanishvili

Animal Molecular Biology Institute of Agricultural University

Supervisor: Giorgi Zaalishvili, PhD




Why antimicrobial peptides?


- Presented in prokaryotes, archaea and eukaryotes
- Broad spectrum of targeted organisms
- Mainly targets polyanionic and/or hydrophobic molecules
- Broad spectrum of antimicrobial characteristics, similar physical properties and evolutionary success

Natural cationic antimicrobial peptides share similar physical properties:

- Small size (12-50 amino acids long)
- Cationicity (overall charge +2 to +9)
- Hydrophobicity
- Amphipathic design




Mechanisms of actions of Cationic Antimicrobial Peptides (CAMPs)




Directly acting CAMPs can be divided as:

- Membrane active
- Intracellularly active


Membrane active Cationic Antimicrobial Peptides



Barrel-stave model, Brogden *et al*



Toroidal pore model, Brogden *et al*.




Carpet model, Brogden *et al*

Cationic Antimicrobial Peptides with intracellular targets


Cationic AMPs that act on:

- Nucleic acids
- Protein synthesis
- Translation and protein folding



Brogden *et al.*

Resistance against Cationic Antimicrobial Peptides



- Degradation of CAMPs by bacterial proteases
- Proteins secreted from bacteria prevent CAMPs from reaching bacterial cell membrane
- Some CAMPs can be actively extruded from bacterial cells
- Bacteria change net anionic charge of their envelope

During the project - 27 synthetic Cationic Antimicrobial Peptide

20 CAMPs designed against gram-negative bacteria:

LCAPL1-LCAPL19, LCAPLD

- 13 amino acid
- C-terminal amidation
- One peptide containing D-amino acids

7 CAMPs designed against gram-positive bacteria:

LifeTein-AMP-1S - 8S

- 13 amino acid
- C-terminal amidation
- One peptide containing D-amino acids

Linear CAMPs were designed in Laboratory of Bioinformatics; I. Beritashvili Center of Experimental Biomedicine, by using semi-supervised machine-learning approach with a density-based clustering algorithm. The suggested algorithm is available on <https://dbaasp.org>

In vitro testing of *In silico* designed CAMPs

- ✓ **Antibacterial activity (MICs)**
- ✓ **Hemolytic activity**
- ✓ **Protease resistance**

Antimicrobial activity

MIC – Minimal Inhibitory Concentration

Antimicrobial activity is affected by:

- Type of the target organism
- *Existence* of Ions in the medium
- Amino acid composition of the peptides

Peptide	MIC (µg/ml)					
	<i>E. coli</i> DH5-α		<i>E. coli</i> ATCC 25922		<i>S. aureus</i> ATCC 25923	
	LB	LB (NaCl supplemented)	LB	LB (NaCl supplemented)	TSB	MHB
LCAPL1	> 3.125	> 12.5	> 3.125	> 25-12.5	>100	>50
LCAPL2	> 3.125	> 6.25	> 3.125	> 12.5-6.25	>100	>25
LCAPL3	> 6.25	> 12.5	> 12.5	> 25	≥100	>25
LCAPL4	> 12.5	> 25	> 6.25	> 25	≥100	>50
LCAPL5	> 6.25	> 50-25	> 12.5	> 100	>100	>100
LCAPL6	> 6.25	> 50-25	> 6.25	> 25	>100	>100
LCAPL7	> 6.25	> 25	> 3.125	> 12.5-6.25	≥100	>25
LCAPL8	> 3.125	< 3.125	> 3.125	> 3.125	≤3.125	≤3.125
LCAPL9	> 12.5	≤ 3.125	> 25-12.5	> 6.25-3.125	≤3.125	≤3.125
LCAPL10	> 3.125	> 6.25	> 6.25	> 6.25-3.125	≥12.5	>3.125
LCAPL11	> 100	> 100	> 50-25	> 50	≥100	>50
LCAPL12	> 100	> 100	> 50	> 100	>100	>100
LCAPL13	> 6.25	> 25	> 3.125	> 12.5	>100	>100
LCAPL14	> 6.25	> 6.25	> 25	> 6.25	>100	>25
LCAPL15	> 3.125	> 3.125	> 3.125	> 3.125	>50	>12.5
LCAPL16	> 100	> 100	> 100	> 100	>100	>100
LCAPL17	> 100	> 100	> 100	> 100	>100	>100
LCAPL18	> 100	> 100	> 25	> 100	>100	>100
LCALL19	> 100	> 100	> 100	> 100	>100	>100
LCAPLD	≤ 3.125	> 6.25-3.125	> 3.125	> 12.5	>100	>50


Table 1. MICs for synthetic Linear Cationic Antimicrobial Peptides designed for *E.coli*

Antimicrobial activity


Peptide	MIC ($\mu\text{g/ml}$)		
	<i>S. aureus</i> ATCC 25924	<i>E. coli</i> ATCC 25922	
	MHB	LB	LB (NaCl supplemented)
LifeTein-AMP-1S	>50	>3.125	>6.25
LifeTein-AMP-2S	>100	>25	>100
LifeTein-AMP-3S	>25	>3.125	>12.5
LifeTein-AMP-4S	≤ 3.125	<3.125	<3.125
LifeTein-AMP-5S	>12.5	<3.125	>25
LifeTein-AMP-6S	>100	>6.25	>100
LifeTein-AMP-8S	≤ 3.125	<3.125	<3.125

Table 2. Antimicrobial activity (MICs) for synthetic Linear Cationic Antimicrobial Peptides designed for *S. aureus*

Hemolytic activity for 20 LCAP



Hemolytic activity for 7 synthetic CAMP




Resistance to proteolysis

Tricine-SDS-PAGE

10µg of peptides were digested by Proteinase K at a molar ratio of 500:1 and 1000:1, respectively. The final concentration of peptides in a reaction mix was 200µg/ml. After 16h incubation at 37°C, protease resistance was analyzed by Tricine-SDS-PAGE, using 4%, 10% and 16% gels.

Results:



Picture 1. Analysis of protease resistance of the designed peptides by Tricine-SDS-PAGE. Lane 1, LCAPL1; Lane 2, LCAPL1 plus Proteinase K (Molar ratio 500:1); Lane 3, LCAPL1 plus Proteinase K (Molar ratio 1000:1); Lane 4, LCAPLD; Lane 5, LCAPLD plus Proteinase K (Molar ratio 500:1); Lane 6, LCAPLD plus Proteinase K (Molar ratio 1000:1).

	Peptide to α -Chymotrypsin Molar ratio		Peptide to Proteinase K Molar ratio	
	1000:1	500:1	1000:1	500:1
BSA	+	+	+	+
LCAPL1	+		+	+
→ LCAPLD	-	-	-	-
LCAPL2	+		+	
LCAPL3	+		+	
LCAPL4	+		partial +	partial +
LCAPL5	+		partial +	partial +
LCAPL6	+		+	
LCAPL7	+		partial +	+
LCAPL8	+		+	
LCAPL9	+		+	
LCAPL10	+		+	
LCAPL11	+		partial +	+
LCAPL12	+		partial +	partial +
LCAPL13	+		partial +	+
LCAPL14	partial +	partial +	partial +	+
LCAPL15	+		+	
LCAPL16	+		+	
LCAPL17	+		+	
LCAPL18	+		+	
LCAPL19	+		+	
LeifTein-AMP-1S	+		+	
LeifTein-AMP-2S	+		+	
LeifTein-AMP-3S	+		partial +	+
LeifTein-AMP-4S	+		partial +	+
LeifTein-AMP-5S	+		-	partial +
→ LeifTein-AMP-6S	+		partial +	+
→ LeifTein-AMP-8S	-	-	-	-

Conclusions

- The predictive tool works
- The antimicrobial activity of the CAMPs is affected by several factors
- There might be a correlation between high hemolytic and high antimicrobial activity
- Peptides are more resistant to Proteinase K than against α -Chymotrypsin